Chemical Information | |
Antiviral agent ID | DrugRepV_6782 | |
Antiviral agent name | Raltegravir | |
IUPAC Name | N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide | |
SMILES (canonical) | CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F | |
Molecular Formula | C20H21FN6O5 | |
Molecular Weight (g/mol) | 444.423 | |
InChl | InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30) | |
Common Name | Raltegravir | |
Structural Information | |
|
|
Clinical Information | |
Category | Antiinfectives For Systemic Use
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Infectious Disease
| |
Primary Indication (Disease) | Acquired immunodeficiency syndrome
| |
Secondary Indication | Human immunodeficiency virus (HIV) 1 97A/Y143R/Q148H | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Drug concentration) | >5000 nM
| |
Secondary Indication (Cell based assay) | Single-round viral replication assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
Reference | Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH..Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants..Retrovirology. 2018 May 16;15(1):37. doi: 10.1186/s12977-018-0420-7. PMID:29769116
| |
Comment | Antiviral activities of Bictegravir and Cabotegravir against primary INSTI-resistant mutants.
| |